{"prompt": "['MC1575', '60', 'Amendment 2', '18.0', 'RECORDS AND DATA COLLECTION PROCEDURES', '18.1', 'Submission Timetable', 'Data submission instructions for this study can be found in the Data Submission Schedule', '(in Medidata RaveR).', '18.2', 'Event monitoring', 'See Section 4.0 and Data Submission Schedule for the event monitoring schedule.', '18.3', 'CRF completion', 'This study will use Medidata Rave for remote data capture (rdc) of all study data.', '18.4', 'Site responsibilities', \"Each site will be responsible for insuring that all materials contain the patient's initials,\", \"MCCC registration number, and MCCC protocol number. Patient's name must be\", 'removed.', '18.5', 'Supporting documentation', 'This study requires supporting documentation for evidence of response to study therapy', 'and progression after study therapy (CR, PR, PD).', '18.6', 'Labelling of materials', \"Each site will be responsible for insuring that all materials contain the patient's initials,\", \"MCCC registration number, and MCCC protocol number. Patient's name must be\", 'removed.', '18.7', 'Incomplete materials', 'Any materials deemed incomplete by the MCCC Operations Office will be considered', '\"not received\" and will not be edited or otherwise processed until the missing', 'information is received. A list of the missing documents will be made available to the', 'appropriate co-sponsor/participant.', '18.8', 'Overdue lists', 'A list of overdue materials and forms for study patients will be generated monthly. The', 'listings will be sorted by location and will include the patient study registration number.', 'The appropriate co-sponsor/participant will be responsible to obtain the overdue material.', '18.9', 'Corrections forms', 'If a correction is necessary the QAS will query the site. The query will be sent to the', 'appropriate site to make the correction and return the query and documentation of', 'correction back to the QAS.', '19.0', 'BUDGET', '19.1', 'Costs charged to patient: routine clinical care', '19.2', 'Tests to be research funded:', '19.3', 'Other budget concerns:', 'Protocol Version Date:16Aug2018']['MC1575', '61', 'Amendment 2', '20.0', 'REFERENCES', 'Amar, L., E. Baudin, et al. (2007). \"Succinate dehydrogenase B gene mutations predict survival in', 'patients with malignant pheochromocytomas or paragangliomas.\" The Journal of clinical', 'endocrinology and metabolism 92(10): 3822-3828.', 'Anderson, G. H., Jr., N. Blakeman, et al. (1994). \"The effect of age on prevalence of secondary forms of', 'hypertension in 4429 consecutively referred patients.\" Journal of hypertension 12(5): 609-615.', 'Averbuch, S. D., C. S. Steakley, et al. (1988). \"Malignant pheochromocytoma: effective treatment with a', 'combination of cyclophosphamide, vincristine, and dacarbazine.\" Annals of internal medicine', '109(4): 267-273.', 'Ayala-Ramirez, M., C.N. Chougnet, et al. (2012). \"Treatment with sunitinib for patients with progressive', 'metastatic pheochromocytomas and sympathetic paragangliomas.\" The Journal of clinical', 'endocrinology and metabolism 97(11): 4040-4050.', 'Ayala-Ramirez, M., L. Feng, et al. (2012). \"Clinical benefits of systemic chemotherapy for patients with', 'metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from', 'the', 'largest single-institutional experience.\" Cancer 118(11): 2804-2812.', 'Ayala-Ramirez, M., L. Feng, et al. (2011). \"Clinical risk factors for malignancy and overall survival', 'in', 'patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and', \"primary tumor location as prognostic indicators.' The Journal of clinical endocrinology and\", 'metabolism 96(3): 717-725.', 'Beard, C. M., S. G. Sheps, et al. (1983). \"Occurrence of pheochromocytoma in Rochester, Minnesota,', '1950 through 1979.\" Mayo Clinic proceedings 58(12): 802-804.', 'Bianchi, L. C., M. Marchetti, et al. (2009). \"Paragangliomas of head and neck: a treatment option with', \"CyberKnife radiosurgery.' Neurological sciences : official journal of the Italian Neurological\", 'Society and of the Italian Society of Clinical Neurophysiology 30(6): 479-485.', 'Bible, K. C., V. J. Suman, et al. (2014). \"A multicenter phase 2 trial of pazopanib in metastatic and', 'progressive medullary thyroid carcinoma: MC057H.\" The Journal of clinical endocrinology and', 'metabolism 99(5): 1687-1693.', 'Bible, K. C., V. J. Suman, et al. (2010). \"Efficacy of pazopanib in progressive, radioiodine-refractory,', \"metastatic differentiated thyroid cancers: results of a phase 2 consortium study.' The Lancet.\", 'Oncology 11(10): 962-972.', 'Boedeker, C. C., G. J. Ridder, et al. (2005). \"Paragangliomas of the head and neck: diagnosis and', 'treatment.\" Familial cancer 4(1): 55-59.', 'Boss, D. S., H. Glen, et al. (2012). \"A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in', 'patients with advanced solid tumours.\" British journal of cancer 106(10): 1598-1604.', 'Bravo, E. L. and R. Tagle (2003). \"Pheochromocytoma: state-of-the-art and future prospects.\" Endocrine', 'reviews 24(4): 539-553.', 'Bukowski, R., D. Cella, et al. (2007). \"Effects of sorafenib on symptoms and quality of life: results from a', 'large randomized placebo-controlled study in renal cancer.\" American journal of clinical', 'oncology 30(3): 220-227.', 'Cairnduff, F. and I. E. Smith (1986). \"Carboplatin chemotherapy for malignant paraganglioma.\\' Lancet', '2(8513): 982.', 'Chrisoulidou, A., G. Kaltsas, et al. (2007). \"The diagnosis and management of malignant', \"phaeochromocytoma and paraganglioma.' Endocrine-related cancer 14(3): 569-585.\", 'Dahia, P. L. (2006). \"Evolving concepts in pheochromocytoma and paraganglioma.\\' Current opinion in', 'oncology 18(1): 1-8.', 'Dahia, P. L. (2006). \"Transcription association of VHL and SDH mutations link hypoxia and', \"oxidoreductase signals in pheochromocytomas.' Annals of the New York Academy of Sciences\", '1073: 208-220.', 'Dahia, P. L., K. N. Ross, et al. (2005). \"A HIF 1alpha regulatory loop links hypoxia and mitochondrial', \"signals in pheochromocytomas.' PLoS genetics 1(1): 72-80.\", 'Protocol Version late:16Aug2018']\n\n###\n\n", "completion": "END"}